CGT Industry Upgrade Series – Nanjing Biopharma Valley Stop: Event Highlights and Ecosystem Collaboration

Liu Xiao

Hangzhou Xingcheng Biotechnology Co., Ltd., Vice President of Business and Marketing

Deputy Director of the MAH Committee of the China Pharmaceutical Enterprise Management Association

Dr. Liu Xiao, Ph.D. in Strategy from Université de Montpellier, EMBA from Nankai University, Master of Biology from the University of Manchester, and graduate student in Finance from the University of Hong Kong. Currently pursuing a Master's degree in Psychology from Arizona State University. Professor at UCMT, Honorary Director of GDA. Senior Engineer in Measurement, Testing, and Instrumentation in China. Dissertation advisor for Ph.D. in Health Management, DBA, and MBA at Université de Montpellier; Guest Lecturer at workshops of the University of Hong Kong Business School and Nankai University Business School; Instructor at the Peking University Health Science Center’s Biopharmaceutical Senior Leadership Training Program; and Special Lecturer at Yihong Business School. Deputy Chairman of the MAH Committee of the China Pharmaceutical Enterprise Management Association, Chief Researcher at the E-Pharma Manager Life Sciences Enterprise Research Center, and Special Researcher at the China Biomedical Infrastructure Alliance. Planner/Host of the "ChatCGT" program.

Formerly served as the Head of Marketing for Danaher's Biotechnology Group in Greater China, and held positions such as APAC Marketing Director, Greater China Marketing Director, Consumables Sales Management, Business Development Manager, and Product Manager at companies like Cytiva, GE Life Sciences, PerkinElmer, and Thermo Fisher Scientific.

Gao Jinquan

Life Biosciences Vice General Manager and General Manager of the Large Animal Model Development Department

Graduated from the Institute of Medical Experimental Animal Science, Chinese Academy of Medical Sciences, focusing on animal surgery, disease model construction, and efficacy evaluation. Successfully established various large animal models of diseases, especially skilled in preparing NHP neurological disease models, including Parkinson's disease models, amyotrophic lateral sclerosis models, Alzheimer's disease models, spinal cord injury models, stroke models, etc., and has provided model development and efficacy services for multiple CNS drug research and development enterprises. Possesses excellent surgical skills and animal experimental techniques, familiar with animal B-ultrasound, CT, PET-CT, and MRI imaging detection. Also proficient in stereotactic injection techniques in monkey brains, as well as superovulation, oocyte retrieval, embryo transfer, and cesarean section techniques in monkeys. Participated in several national major projects and disease model R&D programs.

Xu Lingli

Senior Scientist at Danaher Life Sciences

Xu Lingli is responsible for the overall solutions and market promotion of biopharmaceuticals and cell and gene therapy in Danaher's Life Sciences division. She joined Danaher in 2012 and has since worked at Beckman Coulter and SCIEX, engaging in technical support and marketing related to capillary electrophoresis and capillary electrophoresis genetic analyzers. She is familiar with molecular biology and protein detection technologies, as well as their applications in characterization, quality control, and clinical testing for biopharmaceuticals and cell and gene therapies.

Has assisted multiple institutions, such as Shanghai Huadong Hospital, Beijing Children's Hospital, Hebei Children's Hospital, and the National CDC Virus Institute, in establishing multiplex gene detection methods based on capillary electrophoresis genetic analyzers. Examples include HPV genotyping, CYP2C19 SNP, and leukemia gene typing, among other testing projects. Has co-authored and helped publish several SCI articles based on capillary electrophoresis genetic analyzers. Led and participated in the development of multiple standard methods for capillary electrophoresis, such as the method for plasmid topology analysis in collaboration with the Cell Room of the National Institutes for Food and Drug Control (this method has been published in two articles, approved by the Pharmacopoeia Commission, and will be announced soon). Also collaborated with the Shanghai Institute of Metrology on the establishment of standards like the calibration specifications for capillary electrophoresis.

Ren Jiangtao

Bioheng CEO

Published 20 papers as corresponding author and first author in journals such as "Cell Stem Cell" and "Cell Research," with multiple articles cited over 400 times individually and a total citation exceeding 2000 times; applied for 75 invention patents in cell and gene therapy (10 authorized), including 21 PCT patents, with several patented technologies licensed out; participated in the development of five Class 1 innovative biologic drugs, collaborated on key National Natural Science Foundation gene therapy projects, and the National Key R&D Program's "Frontier Biotechnology" key special projects; frequently invited to present research findings at international conferences.

Li Junhui

Vice President of Science, Technology, and Production at Hangzhou Xingcheng Biotechnology Co., Ltd.

LI Junhui, Ph.D. in Biochemical Engineering from East China University of Science and Technology. MBA from Antai Management School of Shanghai Jiao Tong University. With nearly 20 years of experience in biopharmaceutical R&D and industrialization. Formerly served as Production Director at Shanghai Sidansai (ICT) Company. Manager and Director at Shanghai RAAS Blood Products Co., Ltd., responsible for R&D, regulatory affairs, quality management, etc. Familiar with plasmid, lentivirus, CAR-T cell preparation processes and quality control. Experienced in mammalian cell platform process development. Knowledgeable in upstream process development and GMP production of viral vector preparation. Multiple projects led have received IND approval. Possesses extensive team management experience.

Yuan Jun

Head of Pure Bio BioService and CTO of Kangsheng Bio

Dr. Yuan Jun, Vice President of Zhongshan KTS Biotechnology Co., Ltd., graduated from École Centrale de Lyon in France, with 14 years of experience in the biopharmaceutical industry. He has participated in and been responsible for the design and development of innovative protein drugs, completing over 10 pilot-scale R&D projects, successfully filing 7 clinical applications, and achieving 2 industrialization projects.

Tan Guosheng

Yeasen Key Account Director

Dr. Chen Yijun, graduated from the National University of Singapore School of Medicine, has over a decade of experience in research within the biotechnology and pharmaceutical fields as well as industrial investment. He has worked at Singapore General Hospital, Esco Group in Singapore, and Grand Pharmaceutical (China). In 2008, he began research on antisense nucleic acid drugs in the field of neurodegenerative diseases, later focusing on tumor endocrinology, translational oncology, precision oncology, and also Biotech industry investments. In 2019, he joined the Overseas Division of Grand Pharmaceutical Group, and subsequently founded the mRNA drug development company Nanjing Aoluo Biotechnology Co., Ltd. (Grand Pharmaceutical), where he serves as the Managing Director.

Guo Zebiao Bronson Koh

Malaysian

Assistant to the President of ETANA / Head of BD in China

Dr. Bronson Koh, founding team of Indonesia BBI – involved in one of the first projects in China for pharmaceuticals expanding to Southeast Asia with technology transfer. Participated locally in factory planning and construction, established the initial team, coordinated enterprises from both China and Indonesia, and facilitated the technology transfer of small molecule APIs and formulations for local production.

Current Position: Assistant to the President of Etana / Head of BD in China – Project Introduction, aligning with local policies to export domestically mature products and transfer technology to Southeast Asia, while assisting in establishing supply chains and corresponding systems; also participating in the company's investment and financing projects during this period.

Chen Yijun

CEO of Yuanmai Bio

Dr. Chen Yijun, graduated from the National University of Singapore School of Medicine, has over a decade of experience in research within the biotechnology and pharmaceutical fields as well as industry investment. He has worked at Singapore General Hospital, Esco Group in Singapore, and Grand Pharmaceutical (China). In 2008, he began research on antisense nucleic acid drugs in the field of neurodegenerative diseases, and later focused on tumor endocrinology, translational oncology, precision oncology research, and Biotech industry investment. In 2019, he joined the Overseas Division of Grand Pharmaceutical Group, and subsequently founded an mRNA drug development company, Nanjing Aoluo Biotechnology Co., Ltd. (Grand Pharmaceutical), where he serves as the Managing Director.

Xu Xiao

Founder of Life Biosciences

Dr. Xu Xiao, Ph.D. from the French National Centre for Scientific Research. He has served as the Senior Vice President of Elpiscience Biopharma, responsible for the company's in vitro cell research and application, the construction of the national stem cell bank, external strategic cooperation, intellectual property, regulatory affairs, and more. Prior to this, he worked at Jiuda Pharmaceutical Beijing R&D Center, leading multiple preclinical new drug development projects and participating in the establishment of various drug development platforms. He has received funding from Jiangsu Province’s Innovation and Entrepreneurship Program for Returned Overseas Students, Nanjing City’s Outstanding Returnee Talent Funding Program, and Nanjing City’s Zijin Mountain Talent Plan; he was recognized as a Rising Star in Shanghai Zhangjiang’s Life Science Industry in 2022. He serves as a young editorial board member of the journal "Progress in Pharmaceutical Sciences" at China Pharmaceutical University and is a committee member of the Cell and Gene Therapy Committee of the China Association for the Study of Drug Regulation.